New drugs and novel targets for treatment of invasive fungal infections in patients with cancer.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  The Oncologist

• Publication date

  2000-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1634/THEONCOLOGIST.5-2-120PMID 10794803
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Emerging Targets in Antibacterial and Antifungal Chemotherapy

  2012cited by this paper
• Interscience Conference on Antimicrobial Agents and Chemotherapy

  2001cited by this paper
• Lipid formulations of amphotericin B.

  2000cited by this paper
• Comparison of a New Triazole Antifungal Agent, Schering 56592, with Itraconazole and Amphotericin B for Treatment of Histoplasmosis in Immunocompetent Mice

  1999cited by this paper
• Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics.

  1999cited by this paper
• Antifungal Activity of LY303366, a Novel Echinocandin B, in Experimental Disseminated Candidiasis in Rabbits

  1999cited by this paper
• Current and Emerging Azole Antifungal Agents

  1999cited by this paper
• Activity of Voriconazole, a New Triazole, Combined with Neutrophils or Monocytes against Candida albicans: Effect of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor

  1998cited by this paper
• In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.

  1998cited by this paper
• In vitro efficacy and fungicidal activity of voriconazole againstAspergillus andFusarium species

  1998cited by this paper
• Lipid formulations of amphotericin B: clinical efficacy and toxicities.

  1998cited by this paper
• Antifungal Efficacy, Safety, and Single-Dose Pharmacokinetics of LY303366, a Novel Echinocandin B, in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

  1998cited by this paper
• Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.

  1998cited by this paper
• Efficacy of Nikkomycin Z in the Treatment of Murine Histoplasmosis

  1998cited by this paper
• Antifungal Activity of the Pradimicin Derivative BMS 181184 in the Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

  1998cited by this paper
• In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin

  1998cited by this paper
• Efficacy of MK-991 (L-743,872), a Semisynthetic Pneumocandin, in Murine Models ofPneumocystis carinii

  1998cited by this paper
• Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.

  1998cited by this paper
• In Vitro Susceptibilities of CandidaBloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole

  1998cited by this paper
• Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development.

  1998cited by this paper
• In Vitro Activity of the Echinocandin Antifungal Agent LY303,366 in Comparison with Itraconazole and Amphotericin B against Aspergillus spp

  1998cited by this paper
• Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts

  1998cited by this paper
• Efficacy of LY303366 against Amphotericin B-Susceptible and -Resistant Aspergillus fumigatus in a Murine Model of Invasive Aspergillosis

  1998cited by this paper
• Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS.

  1998cited by this paper
• Compartmental Pharmacokinetics and Tissue Drug Distribution of the Pradimicin Derivative BMS 181184 in Rabbits

  1998cited by this paper
• Pradimicin therapy of disseminated Candida tropicalis infection in the mouse.

  1998cited by this paper
• In Vitro Activities of Voriconazole (UK-109,496) and Four Other Antifungal Agents against 394 Clinical Isolates ofCandida spp

  1998cited by this paper
• Susceptibilities of Candida Species Isolated from the Lower Gastrointestinal Tracts of High-Risk Patients to the New Semisynthetic Echinocandin LY303366 and Other Antifungal Agents

  1998cited by this paper
• Treatment of Histoplasmosis with MK-991 (L-743,872)

  1998cited by this paper
• Granulocyte Colony-Stimulating Factor and Azole Antifungal Therapy in Murine Aspergillosis: Role of Immune Suppression

  1998cited by this paper
• Use of Voriconazole in Treatment ofScedosporium apiospermum Infection: Case Report

  1998cited by this paper
• Sordarins: In Vitro Activities of New Antifungal Derivatives against Pathogenic Yeasts, Pneumocystis carinii, and Filamentous Fungi

  1998cited by this paper
• In vitro activity of voriconazole against selected fungi.

  1998cited by this paper
• In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346)

  1998cited by this paper
• In Vitro Comparative Efficacy of Voriconazole and Itraconazole against Fluconazole-Susceptible and -Resistant Cryptococcus neoformans Isolates

  1998cited by this paper
• Sordarins: A New Class of Antifungals with Selective Inhibition of the Protein Synthesis Elongation Cycle in Yeasts

  1998cited by this paper
• SCH56592 treatment of murine invasive aspergillosis.

  1998cited by this paper
• Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.

  1998cited by this paper
• Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis

  1997cited by this paper
• Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.

  1997cited by this paper
• The search for new triazole antifungal agents.

  1997cited by this paper
• In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species

  1997cited by this paper
• In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts

  1997cited by this paper
• POTENTIAL NEW ANTIFUNGAL AGENTS

  1997cited by this paper
• In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents

  1997cited by this paper
• Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice

  1997cited by this paper
• In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection

  1997cited by this paper
• Efficacy of nikkomycin Z against experimental pulmonary blastomycosis

  1997cited by this paper
• Echinocandins and pneumocandins--a new antifungal class with a novel mode of action.

  1997cited by this paper
• Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients

  1997cited by this paper
• Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

  1997cited by this paper
• Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus

  1997cited by this paper
• International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections.

  1997cited by this paper
• Treatment of murine disseminated candidiasis with L-743,872

  1997cited by this paper
• In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species

  1997cited by this paper
• Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia

  1997cited by this paper
• Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection.

  1997cited by this paper
• Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro

  1997cited by this paper
• In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species

  1997cited by this paper
• Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia

  1997cited by this paper
• In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

  1997cited by this paper
• Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs

  1997cited by this paper
• In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens

  1997cited by this paper
• Myelofibrosis complicated by infection due to Candida albicans: emergence of resistance to antifungal agents during therapy.

  1997cited by this paper
• In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp

  1997cited by this paper
• Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation.

  1997cited by this paper
• Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)

  1997cited by this paper
• Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans

  1997cited by this paper
• Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis

  1997cited by this paper
• Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp

  1997cited by this paper
• Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis

  1996cited by this paper
• In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species

  1996cited by this paper
• Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis

  1996cited by this paper
• Invasive fungal infections in children: recent advances in diagnosis and treatment.

  1996cited by this paper
• Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients.

  1996cited by this paper
• Lipid formulations of amphotericin B: recent progress and future directions.

  1996cited by this paper
• Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study.

  1996cited by this paper
• In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis

  1996cited by this paper
• In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum

  1996cited by this paper
• In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans

  1996cited by this paper
• Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature.

  1996cited by this paper
• Trends in the postmortem epidemiology of invasive fungal infections at a university hospital.

  1996cited by this paper
• In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp

  1996cited by this paper
• The in-vitro activity of an antifungal antibiotic benanomicin A in comparison with amphotericin B.

  1996cited by this paper
• Lipid formulations of amphotericin B.

  1996cited by this paper
• In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184

  1995cited by this paper
• Section Review: Anti-infectives: The potential of novel antifungal drugs for the treatment of disease in the immunocompromised host

  1995cited by this paper
• Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis

  1995cited by this paper
• Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.

  1995cited by this paper
• A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

  1994cited by this paper
• A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia

  1994cited by this paper
• Antibiotics that inhibit fungal cell wall development.

  1994cited by this paper
• Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome.

  1994cited by this paper
• Evolving risk factors for invasive fungal infections--all neutropenic patients are not the same.

  1994cited by this paper
• In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis.

  1994cited by this paper
• NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis.

  1994cited by this paper
• Compounds active against cell walls of medically important fungi

  1993cited by this paper
• Impact of the changing epidemiology of fungal infections in the 1990s

  1992cited by this paper
• Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment.

  1992cited by this paper
• Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo

  1992cited by this paper

• Intratumor fungi specific mechanisms to influence cell death pathways and trigger tumor cell apoptosis

  2025cites this paper
• Overcoming antifungal resistance in Candida albicans via RNA interference: a therapeutic perspective

  2025cites this paper
• Tailoring Phage Nanosomes for Enhanced Theranostic Properties of Near Infrared Dyes.

  2024cites this paper
• Bioinspired Gold coated Phage Nanosomes for Anti-Microbial and Anti-Cancer Theranostics

  2023cites this paper
• Utilizing 4D Printing to Design Smart Gastroretentive, Esophageal, and Intravesical Drug Delivery Systems

  2022cites this paper
• Immunotherapy and Antifungal Drugs of Candidiasis: Achievements and Challenges

  2021cites this paper
• Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges

  2020cites this paper
• Pharmacokinetics and Safety of Two Voriconazole Formulations after Intravenous Infusion in Healthy Korean Volunteers

  2020cites this paper
• Therapeutic drug monitoring for antifungal triazoles: pharmacologic background and current status

  2020cites this paper
• The Triazole Ring as a Privileged Scaffold for Putative Antifungals: Synthesis and Evaluation of a Series of New Analogues

  2020cites this paper
• A pharmacokinetic model for voriconazole in a highly diversified population of children and adolescents with cancer

  2019cites this paper
• Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases.

  2019cites this paper
• Imaging Fungal Infections and Therapy Follow-Up

  2019cites this paper
• Role of Antifungal Drugs in Combating Invasive Fungal Diseases

  2019cites this paper
• An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.

  2017cites this paper
• The Role of PET in Monitoring Therapy in Fungal Infections.

  2017cites this paper
• Comparative effectiveness of chemical biocides and Acalypha wilkesiana leaf extract against postharvest fungal deteriogens of sweet orange (Citrus sinensis) fruits

  2017cites this paper
• Molecular Targets for Anticandidal Chemotherapy

  2017cites this paper
• Ruthenium Complexes as Antifungal Agents

  2017cites this paper
• Invasive Aspergillosis in Cancer Patients

  2017cites this paper
• EFFICACY OF MICAFUNGIN IN EMPIRICAL , PREEMPTIVE AND TARGETED THERAPY OF INVASIVE FUNGAL DISEASE IN CHILDREN WITH MALIGNANCY OR UNDERGOING STEM CELL TRANSPLANTATION

  2016cites this paper
• Micafungin in invasive fungal infections in children with acute leukemia or undergoing stem cell transplantation

  2016cites this paper
• History of antifungals

  2016cites this paper
• Effect of Rutaceae plant's essential oils and leaf extracts on dermatophytic fungal cell morphology : a hope for the development of an effective antifungal from natural origin.

  2016influential citation
• Assessing patient characteristics and radiation-induced non-targeted effects in vivo for high dose-rate (HDR) brachytherapy

  2015cites this paper
• Immunotherapy of Fungal Infections

  2015cites this paper
• The activity of micafungin against clinical isolates of non-albicans Candida spp.

  2015cites this paper
• Fractal and stochastic geometry inference for breast cancer: a case study with random fractal models and Quermass‐interaction process

  2015cites this paper
• Yeasts isolated from frequently in-patients and out-patients.

  2014cites this paper
• Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation

  2014cites this paper
• In Vitro Studies of the Activity of Dithiocarbamate Organoruthenium Complexes against Clinically Relevant Fungal Pathogens

  2014cites this paper
• Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole

  2014cites this paper
• Voriconazole in the Treatment of Invasive Aspergillosis: profile report

  2013cites this paper
• Host-Fungal Interactions: Pathogenicity versus Immunity

  2012influential citation
• Caspofungin

  2012cites this paper
• Current and Future Therapeutic Options in the Management of Invasive Aspergillosis

  2012cites this paper
• Amentoflavone Stimulates Mitochondrial Dysfunction and Induces Apoptotic Cell Death in Candida albicans

  2012cites this paper
• Newer Systemic Antifungal Agents

  2012cites this paper
• Caspofungin

  2012cites this paper
• Elaboration of antibiofilm surfaces functionalized with antifungal-cyclodextrin inclusion complexes.

  2012cites this paper
• Pharmacogenetics and Dermatology

  2012cites this paper
• Voriconazole In the Treatment of Invasive Aspergillosis

  2012cites this paper
• First case report of acquired pure red cell aplasia associated with micafungin.

  2011cites this paper
• Antifungal Resistance and New Strategies to Control Fungal Infections

  2011influential citation
• Dual Properties of Anticancer Agents: An Exploratory Study on the in vitro Anti-Candida Properties of Thirty Drugs

  2011cites this paper
• Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration.

  2011cites this paper
• Pharmacogenomics of the triazole antifungal agent voriconazole.

  2011cites this paper
• CHAPTER 37 – Clinical Pharmacology of Anti-Infective Drugs

  2011cites this paper
• The elucidation of signalling and survival mechanisms of fungi to counteract the antifungal protein AFP

  2011cites this paper
• Chapter 1

  2011influential citation
• Conazoles

  2010cites this paper
• Challenges to the Management of Pulmonary Mycoses in Allogeneic Hematopoietic Stem Cell Transplantation

  2010cites this paper
• Disruption of fungal cell wall by antifungal Echinacea extracts.

  2010cites this paper
• 03 Rodriguez-Review.indd

  2009influential citation
• Antifungal research strategies aiming for new targets.

  2009influential citation
• Baicalein induces programmed cell death in Candida albicans.

  2009cites this paper
• The impact of total bilirubin on plasma micafungin levels in living-donor liver transplantation recipients with severe liver dysfunction.

  2009cites this paper
• review article antifungal research Strategies aiming for New t argets

  2009cites this paper
• Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation.

  2008cites this paper
• Antifungal Immunotherapy and Immunomodulation: A Double‐hitter Approach to Deal with Invasive Fungal Infections

  2008cites this paper
• Mécanismes moléculaires de la résistance aux antifongiques chez candida glabrata

  2008influential citation
• Anidulafungin: a new echinocandin for candidal infections

  2007cites this paper
• Novel Antifungal Therapies

  2007cites this paper
• Antifungal activity of a novel compound from Burkholderia cepacia against plant pathogenic fungi

  2007cites this paper
• Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis.

  2006cites this paper
• Prevention and Treatment of Infectious Disease

  2006cites this paper
• IN VITRO SYNERGISM BETWEEN MICONAZOLE AND GRISEOFULVIN AGAINST CANDIDA SPECIES

  2006cites this paper
• The structure and synthesis of the fungal cell wall

  2006cites this paper
• Successful treatment of patients with respiratory failure due to fungal infection after allogeneic hematopoietic stem cell transplantation

  2005cites this paper
• Haemopoietic progenitor cell transplantation in patients with previous history of invasive fungal infection

  2005cites this paper
• Modern management of respiratory failure due to pulmonary mycoses following allogeneic hematopoietic stem‐cell transplantation

  2005cites this paper
• Antifungal agents in children.

  2005cites this paper
• Antifungal treatment in pediatric patients.

  2005cites this paper
• Fármacos antifúngicos. Situación actual y pautas para su administración

  2005cites this paper
• [Anti-fungal drugs. Current status and guidelines for their administration].

  2005cites this paper
• New antifungal agents under development in children and neonates

  2005cites this paper
• A fraction from Escherichia coli with anti-Aspergillus properties.

  2005cites this paper
• Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation

  2005cites this paper
• History of the development of azole derivatives.

  2004cites this paper
• Single-or Multiple-Dose Administration Intravenous Voriconazole in Children after Pharmacokinetics and Safety of

  2004cites this paper
• Echinocandins: A promising new antifungal group

  2004cites this paper
• Desk encyclopedia of microbiology

  2004cites this paper
• Antifungal Agents: In Vitro Susceptibility Testing, Pharmacodynamics, and Prospects for Combination Therapy

  2004cites this paper
• Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients

  2004cites this paper
• Improved Outcome of Zygomycosis in Patients with Hematological Diseases?

  2004cites this paper
• In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus.

  2004cites this paper
• Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration

  2004cites this paper
• Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis

  2004cites this paper
• Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

  2004cites this paper
• Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

  2004cites this paper
• Hemorrhagic bowel syndrome in dairy cattle and efficacy of feed additive in stimulating immune response in livestock

  2004cites this paper
• Population Pharmacokinetic Analysis of Anidulafungin, an Echinocandin Antifungal

  2004cites this paper
• Clinical pharmacology of antifungal compounds.

  2003influential citation
• Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.

  2003cites this paper
• Antifungal Tedavide Yenilikler

  2003cites this paper
• Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.

  2003cites this paper
• Recent Developments in Epidemiology and Management of Invasive Fungal Infections

  2003cites this paper
• Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis.

  2003cites this paper
• Caspofungin: the first in a new class of antifungal agents.

  2003cites this paper
• Successful treatment of Scedosporium pneumonia with voriconazole during AML therapy and bone marrow transplantation.

  2003cites this paper